ACVR1
ENSG00000115170
Target class
Kinase
Chromosome
2
Approved drugs
4
Clinical candidates (approved and in development)
4
- Approved drugs
- 4
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- Yes
- Target name
- ACVR1
- Gene name
- Activin A receptor type 1
- Gene symbol
- ACVR1
- Previous gene symbols
- ACVRLK2
- Protein name
- Activin receptor type-1 (EC 2.7.11.30) (Activin receptor type I) (ACTR-I) (Activin receptor-like kinase 2) (ALK-2) (Serine/threonine-protein kinase receptor R1) (SKR1) (TGF-B superfamily receptor type I) (TSR-I)
- SKR1
- ALK2
- ACVR1A
- Gene biotype
- Protein coding
- Gene family
- Type 1 receptor serine/threonine kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 53
- Highest tissue expression
- 43.14
- Tissue specificity (Gini)
- 0.368
- Tissue specificity (tau)
- 0.636
- KEGG gene identifiers
- hsa:90
- Protein interaction confidence
- 0.923522
- Protein interaction partners
- 46
- End position
- 157876347
- Start position
- 157736249
- Chromosome
- 2
- Strand
- Reverse
- Membrane
- Single-pass type I membrane protein.
- Tissue specificity (tau)
- 0.635741
- Expression inequality (Gini)
- 0.367595
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 43.14
- Artery - Tibial
- 38.73
- Cervix - Endocervix
- 38.01
- Uterus
- 35.94
- Artery - Aorta
- 35.89
Expression in transcripts per million
- Cells - Cultured fibroblasts43.14
- Artery - Tibial38.73
- Cervix - Endocervix38.01
- Uterus35.94
- Artery - Aorta35.89
- Thyroid34.24
- Cervix - Ectocervix32.27
- Fallopian Tube27.86
- Adipose - Subcutaneous27.61
- Ovary26.8
- Breast - Mammary Tissue26.09
- Artery - Coronary25.58
- Nerve - Tibial24.28
- Bladder24.11
- Vagina23.05
- Minor Salivary Gland22.49
- Colon - Sigmoid21.82
- Esophagus - Muscularis21.73
- Lung21.16
- Adipose - Visceral (Omentum)20.85
- Esophagus - Gastroesophageal Junction19.68
- Skin - Sun Exposed (Lower leg)17.81
- Skin - Not Sun Exposed (Suprapubic)16.71
- Pituitary15.49
- Prostate14.99
And 29 more, listed on the interactive page.
- GO:0001649
- GO:0003143
- GO:0003183
- GO:0003289
- GO:0007179
- GO:0009968
- GO:0030278
- GO:0030335
- GO:0030501
- GO:0030509
- GO:0032924
- GO:0032926
- GO:0045669
- GO:0045893
- GO:0045944
- GO:0060391
- GO:0060923
- GO:0061445
- GO:0071773
- GO:1902533
- GO:2000017
- GO:2000134
- GO:2001237
- GO:0005886
- GO:0048179
- GO:0004672
- GO:0004674
- GO:0004675
- GO:0005515
- GO:0005524
- GO:0016361
- GO:0042803
- GO:0045296
- GO:0046332
- GO:0048185
- GO:0050431
- GO:0098821
- GO:1990782
Related records
Trials (96)
- A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
- A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
- A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
- A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
- A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
- A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
- A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis
- A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
- A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)
- A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
- A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
- A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
- A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
- A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- A Study of rhBMP-2/CPM in Closed Fractures of the Humerus
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
- BMP Effect on Implant Stability and Marginal Bone Level After Immediate Placement
Drugs (6)
- Dibotermin alfa Activin receptor type-1 agonist
- Eptotermin alfa Activin receptor type-1 agonist
- Momelotinib Activin receptor type-1 inhibitor
- Momelotinib dihydrochloride monohydrate Activin receptor type-1 inhibitor
- Pacritinib Activin receptor type-1 inhibitor
- Pacritinib citrate Activin receptor type-1 inhibitor